
|Articles|June 8, 2006
EC awards Allergan license to market bimatoprost/timolol solution
The European Commission (EC) granted Allergan a license to market bimatoprost/timolol ophthalmic solution (Ganfort) in the European Union. The once-daily combination product is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension whose disease is insufficiently responsive to topical beta-blockers or prostaglandin analogues.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
2
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
3
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5

















































.png)


